

Remicade Biosimilar Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (100mg/10ml, 500mg/50ml), By Disease Indication (Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Plaque Psoriasis), By Application

<https://marketpublishers.com/r/RA260C5E47A2EN.html>

Date: October 2025

Pages: 160

Price: US\$ 3,950.00 (Single User License)

ID: RA260C5E47A2EN

Abstracts

The Remicade Biosimilar Market is valued at USD 5.8 billion in 2025 and is projected to grow at a CAGR of 21.7% to reach USD 34 billion by 2034. The Remicade Biosimilar Market has gained substantial momentum in recent years, offering cost-effective alternatives to Johnson & Johnson's blockbuster biologic, Remicade (infliximab). As a monoclonal antibody used to treat autoimmune diseases like rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis, Remicade has seen widespread global usage. Biosimilars such as Inflectra, Renflexis, and Avsola have emerged as competitive therapeutic options, driving significant healthcare savings and expanding patient access to biologic treatments. These biosimilars are developed to match the reference product in terms of efficacy, safety, and immunogenicity but at a lower cost. The market has benefitted from patent expirations, regulatory support, and payer-driven efforts to reduce healthcare expenditure. Hospitals, clinics, and health systems are increasingly adopting biosimilars in place of originator biologics, especially in markets with favorable substitution policies and incentivized pricing models. The market is characterized by intense competition, increasing approvals, and ongoing efforts to boost physician and patient confidence in biosimilar interchangeability. The Remicade biosimilar market saw expanded uptake in both mature and emerging markets, fueled by policy shifts, pricing reforms, and increased physician familiarity. Europe continued to lead in biosimilar adoption due to robust support for automatic substitution and strong institutional frameworks. The U.S. market gained further traction, as key biosimilars like

Inflectra and Renflexis secured broader formulary placements and insurer backing. Several biosimilar manufacturers lowered prices to gain market share, intensifying competition and pressuring originator pricing. Meanwhile, ongoing education campaigns by healthcare authorities and biosimilar producers helped improve prescriber confidence and patient acceptance. In emerging economies, biosimilar access improved through local manufacturing initiatives and WHO prequalification programs. While regulatory hurdles remained in some regions, increasing clarity from health authorities encouraged new players to enter the market. Overall, 2024 marked a period of market consolidation, price-based competition, and growing confidence in the clinical equivalence of Remicade biosimilars. The Remicade biosimilar market is expected to deepen with rising penetration in outpatient settings and community care. Expanded approvals for interchangeability in the U.S. will pave the way for more automatic substitution at pharmacies, significantly accelerating volume growth. In emerging markets, domestic production and technology transfer initiatives will support affordability and availability. Digital tools and real-world data platforms will enhance biosimilar monitoring and reporting, further validating long-term safety and efficacy. Biosimilar companies are expected to invest in patient assistance programs and physician outreach to counter brand loyalty and improve therapy transitions. As pressure mounts to manage chronic disease costs, payers will likely introduce tiered reimbursement policies favoring biosimilars. However, the market will also face challenges from newer biologics and subcutaneous formulations that offer greater convenience. Despite this, Remicade biosimilars will continue to play a key role in broadening access to biologic therapy and driving healthcare system efficiency globally.

Key Insights Remicade Biosimilar Market

Growing acceptance of automatic substitution policies, especially in Europe and potentially the U.S., is accelerating biosimilar uptake in hospital and retail pharmacy settings.

Manufacturers are increasingly offering value-added services such as digital adherence tools, nurse support, and educational platforms to support biosimilar adoption.

Price-based competition is intensifying, with biosimilar makers reducing costs to gain or maintain formulary access and increase market penetration.

Use of real-world evidence and pharmacovigilance platforms is strengthening stakeholder confidence in long-term biosimilar safety and therapeutic outcomes.

Collaborations between multinational pharma companies and local producers are expanding biosimilar manufacturing capabilities in developing regions.

Patent expiry of originator biologics like Remicade is creating strong entry opportunities for biosimilar manufacturers worldwide.

Rising prevalence of autoimmune conditions is fueling demand for cost-effective biologics, making biosimilars a practical alternative for long-term therapy.

Healthcare cost-containment policies and value-based reimbursement models are incentivizing payers and providers to prioritize biosimilar usage.

Supportive regulatory frameworks and faster approval pathways are encouraging biosimilar development and commercialization across major markets.

Brand loyalty, physician hesitancy, and limited interchangeability approvals in some regions continue to pose barriers to rapid adoption of Remicade biosimilars, particularly in outpatient and specialty care settings.

Remicade Biosimilar Market Segmentation

By Type

100mg/10ml

500mg/50ml

By Disease Indication

Ulcerative Colitis

Rheumatoid Arthritis

Ankylosing Spondylitis

Crohn's Disease

Psoriatic Arthritis

Plaque Psoriasis

By Application

Blood Disorders

Oncology Diseases

Key Companies Analysed

AbbVie Inc.

Novartis AG

Amgen Inc

Viartis Inc.

Teva Pharmaceutical Industries Ltd.

Biogen Inc.

Organon & Co.

Merck And Co. Inc.

Janssen Biotech Inc.

LG Chem Ltd.

Nippon Kayaku Co. Ltd.

Celltrion Inc.

Nichi-iko Pharmaceutical Co. Ltd.

Biocon Limited

Alvogen Inc

Synthon International Holding B.V.

Coherus Biosciences Inc

Cardinal Health Inc

Genentech Inc.

Alvotech S.A.

MabPharm Ltd.

Genor Biopharma Co. Ltd

Shanghai Biomabs Pharmaceuticals Co. Ltd.

Samsung Bioepis Co. Ltd.

Biocad Biopharmaceutical Co

EPIRUS Biopharmaceuticals Inc.

Ranbaxy Laboratories Limited

BioXpress Therapeutics SA

Mabion S.A

Remicade Biosimilar Market Analytics

The report employs rigorous tools, including Porter's Five Forces, value chain mapping,

Remicade Biosimilar Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (100mg/10ml, 500mg/50m...

and scenario-based modeling, to assess supply–demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Remicade Biosimilar Market Competitive Intelligence

The competitive landscape is mapped through OG Analysis' proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

North America — Remicade Biosimilar market data and outlook to 2034

United States

Canada

Mexico

Europe — Remicade Biosimilar market data and outlook to 2034

Germany

United Kingdom

France

Italy

Spain

BeNeLux

Russia

Sweden

Asia-Pacific — Remicade Biosimilar market data and outlook to 2034

China

Japan

India

South Korea

Australia

Indonesia

Malaysia

Vietnam

Middle East and Africa — Remicade Biosimilar market data and outlook to 2034

Saudi Arabia

South Africa

Iran

UAE

Egypt

South and Central America — Remicade Biosimilar market data and outlook to 2034

Brazil

Argentina

Chile

Peru

** We can include data and analysis of additional countries on demand.*

Research Methodology

This study combines primary inputs from industry experts across the Remicade Biosimilar value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

What is the current and forecast market size of the Remicade Biosimilar industry at global, regional, and country levels?

Which types, applications, and technologies present the highest growth potential?

How are supply chains adapting to geopolitical and economic shocks?

What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?

Who are the leading players, and how are their strategies evolving in the face of global uncertainty?

Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?

Where are the most investable opportunities—across technology roadmaps, sustainability-linked innovation, and M&A—and what is the best segment to invest over the next 3–5 years?

Your Key Takeaways from the Remicade Biosimilar Market Report

Global Remicade Biosimilar market size and growth projections (CAGR), 2024-2034

Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Remicade Biosimilar trade, costs, and supply chains

Remicade Biosimilar market size, share, and outlook across 5 regions and 27 countries, 2023-2034

Remicade Biosimilar market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034

Short- and long-term Remicade Biosimilar market trends, drivers, restraints, and opportunities

Porter’s Five Forces analysis, technological developments, and Remicade Biosimilar supply chain analysis

Remicade Biosimilar trade analysis, Remicade Biosimilar market price analysis, and Remicade Biosimilar supply/demand dynamics

Profiles of 5 leading companies—overview, key strategies, financials, and products

Latest Remicade Biosimilar market news and developments

Additional Support

With the purchase of this report, you will receive

An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.

7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.

Complimentary report update to incorporate the latest available data and the impact of recent market developments.

** The updated report will be delivered within 3 working days*

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL REMICADE BIOSIMILAR MARKET SUMMARY, 2025

- 2.1 Remicade Biosimilar Industry Overview
 - 2.1.1 Global Remicade Biosimilar Market Revenues (In US\$ billion)
- 2.2 Remicade Biosimilar Market Scope
- 2.3 Research Methodology

3. REMICADE BIOSIMILAR MARKET INSIGHTS, 2024-2034

- 3.1 Remicade Biosimilar Market Drivers
- 3.2 Remicade Biosimilar Market Restraints
- 3.3 Remicade Biosimilar Market Opportunities
- 3.4 Remicade Biosimilar Market Challenges
- 3.5 Tariff Impact on Global Remicade Biosimilar Supply Chain Patterns

4. REMICADE BIOSIMILAR MARKET ANALYTICS

- 4.1 Remicade Biosimilar Market Size and Share, Key Products, 2025 Vs 2034
- 4.2 Remicade Biosimilar Market Size and Share, Dominant Applications, 2025 Vs 2034
- 4.3 Remicade Biosimilar Market Size and Share, Leading End Uses, 2025 Vs 2034
- 4.4 Remicade Biosimilar Market Size and Share, High Growth Countries, 2025 Vs 2034
- 4.5 Five Forces Analysis for Global Remicade Biosimilar Market
 - 4.5.1 Remicade Biosimilar Industry Attractiveness Index, 2025
 - 4.5.2 Remicade Biosimilar Supplier Intelligence
 - 4.5.3 Remicade Biosimilar Buyer Intelligence
 - 4.5.4 Remicade Biosimilar Competition Intelligence
 - 4.5.5 Remicade Biosimilar Product Alternatives and Substitutes Intelligence
 - 4.5.6 Remicade Biosimilar Market Entry Intelligence

5. GLOBAL REMICADE BIOSIMILAR MARKET STATISTICS – INDUSTRY REVENUE, MARKET SHARE, GROWTH TRENDS AND FORECAST BY SEGMENTS, TO 2034

5.1 World Remicade Biosimilar Market Size, Potential and Growth Outlook, 2024- 2034 (\$ billion)

5.1 Global Remicade Biosimilar Sales Outlook and CAGR Growth By Type, 2024- 2034 (\$ billion)

5.2 Global Remicade Biosimilar Sales Outlook and CAGR Growth By Disease Indication, 2024- 2034 (\$ billion)

5.3 Global Remicade Biosimilar Sales Outlook and CAGR Growth By Application, 2024- 2034 (\$ billion)

5.4 Global Remicade Biosimilar Market Sales Outlook and Growth by Region, 2024- 2034 (\$ billion)

6. ASIA PACIFIC REMICADE BIOSIMILAR INDUSTRY STATISTICS – MARKET SIZE, SHARE, COMPETITION AND OUTLOOK

6.1 Asia Pacific Remicade Biosimilar Market Insights, 2025

6.2 Asia Pacific Remicade Biosimilar Market Revenue Forecast By Type, 2024- 2034 (USD billion)

6.3 Asia Pacific Remicade Biosimilar Market Revenue Forecast By Disease Indication, 2024- 2034 (USD billion)

6.4 Asia Pacific Remicade Biosimilar Market Revenue Forecast By Application, 2024- 2034 (USD billion)

6.5 Asia Pacific Remicade Biosimilar Market Revenue Forecast by Country, 2024- 2034 (USD billion)

6.5.1 China Remicade Biosimilar Market Size, Opportunities, Growth 2024- 2034

6.5.2 India Remicade Biosimilar Market Size, Opportunities, Growth 2024- 2034

6.5.3 Japan Remicade Biosimilar Market Size, Opportunities, Growth 2024- 2034

6.5.4 Australia Remicade Biosimilar Market Size, Opportunities, Growth 2024- 2034

7. EUROPE REMICADE BIOSIMILAR MARKET DATA, PENETRATION, AND BUSINESS PROSPECTS TO 2034

7.1 Europe Remicade Biosimilar Market Key Findings, 2025

7.2 Europe Remicade Biosimilar Market Size and Percentage Breakdown By Type, 2024- 2034 (USD billion)

7.3 Europe Remicade Biosimilar Market Size and Percentage Breakdown By Disease Indication, 2024- 2034 (USD billion)

7.4 Europe Remicade Biosimilar Market Size and Percentage Breakdown By Application, 2024- 2034 (USD billion)

7.5 Europe Remicade Biosimilar Market Size and Percentage Breakdown by Country, 2024- 2034 (USD billion)

7.5.1 Germany Remicade Biosimilar Market Size, Trends, Growth Outlook to 2034

7.5.2 United Kingdom Remicade Biosimilar Market Size, Trends, Growth Outlook to 2034

7.5.2 France Remicade Biosimilar Market Size, Trends, Growth Outlook to 2034

7.5.2 Italy Remicade Biosimilar Market Size, Trends, Growth Outlook to 2034

7.5.2 Spain Remicade Biosimilar Market Size, Trends, Growth Outlook to 2034

8. NORTH AMERICA REMICADE BIOSIMILAR MARKET SIZE, GROWTH TRENDS, AND FUTURE PROSPECTS TO 2034

8.1 North America Snapshot, 2025

8.2 North America Remicade Biosimilar Market Analysis and Outlook By Type, 2024- 2034 (\$ billion)

8.3 North America Remicade Biosimilar Market Analysis and Outlook By Disease Indication, 2024- 2034 (\$ billion)

8.4 North America Remicade Biosimilar Market Analysis and Outlook By Application, 2024- 2034 (\$ billion)

8.5 North America Remicade Biosimilar Market Analysis and Outlook by Country, 2024- 2034 (\$ billion)

8.5.1 United States Remicade Biosimilar Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.5.1 Canada Remicade Biosimilar Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.5.1 Mexico Remicade Biosimilar Market Size, Share, Growth Trends and Forecast, 2024- 2034

9. SOUTH AND CENTRAL AMERICA REMICADE BIOSIMILAR MARKET DRIVERS, CHALLENGES, AND FUTURE PROSPECTS

9.1 Latin America Remicade Biosimilar Market Data, 2025

9.2 Latin America Remicade Biosimilar Market Future By Type, 2024- 2034 (\$ billion)

9.3 Latin America Remicade Biosimilar Market Future By Disease Indication, 2024- 2034 (\$ billion)

9.4 Latin America Remicade Biosimilar Market Future By Application, 2024- 2034 (\$ billion)

9.5 Latin America Remicade Biosimilar Market Future by Country, 2024- 2034 (\$ billion)

9.5.1 Brazil Remicade Biosimilar Market Size, Share and Opportunities to 2034

9.5.2 Argentina Remicade Biosimilar Market Size, Share and Opportunities to 2034

10. MIDDLE EAST AFRICA REMICADE BIOSIMILAR MARKET OUTLOOK AND GROWTH PROSPECTS

10.1 Middle East Africa Overview, 2025

10.2 Middle East Africa Remicade Biosimilar Market Statistics By Type, 2024- 2034 (USD billion)

10.3 Middle East Africa Remicade Biosimilar Market Statistics By Disease Indication, 2024- 2034 (USD billion)

10.4 Middle East Africa Remicade Biosimilar Market Statistics By Application, 2024- 2034 (USD billion)

10.5 Middle East Africa Remicade Biosimilar Market Statistics by Country, 2024- 2034 (USD billion)

10.5.1 Middle East Remicade Biosimilar Market Value, Trends, Growth Forecasts to 2034

10.5.2 Africa Remicade Biosimilar Market Value, Trends, Growth Forecasts to 2034

11. REMICADE BIOSIMILAR MARKET STRUCTURE AND COMPETITIVE LANDSCAPE

11.1 Key Companies in Remicade Biosimilar Industry

11.2 Remicade Biosimilar Business Overview

11.3 Remicade Biosimilar Product Portfolio Analysis

11.4 Financial Analysis

11.5 SWOT Analysis

12 APPENDIX

12.1 Global Remicade Biosimilar Market Volume (Tons)

12.1 Global Remicade Biosimilar Trade and Price Analysis

12.2 Remicade Biosimilar Parent Market and Other Relevant Analysis

12.3 Publisher Expertise

12.2 Remicade Biosimilar Industry Report Sources and Methodology

I would like to order

Product name: Remicade Biosimilar Market Outlook 2025-2034: Market Share, and Growth Analysis By Type (100mg/10ml, 500mg/50ml), By Disease Indication (Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Plaque Psoriasis), By Application

Product link: <https://marketpublishers.com/r/RA260C5E47A2EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RA260C5E47A2EN.html>